We report that in breast cancer cells, tyrosine phosphorylation of the estradiol receptor alpha (ERalpha) by Src regulates cytoplasmic localization of the receptor and DNA synthesis. Inhibition of Src or use of a peptide mimicking the ERalpha p-Tyr537 sequence abolishes ERalpha tyrosine phosphorylation and traps the receptor in nuclei of estradiol-treated MCF-7 cells. An ERalpha mutant carrying a mutation of Tyr537 to phenylalanine (ER537F) persistently localizes in nuclei of various cell types. In contrast with ERalpha wt, ER537F does not associate with Ran and its interaction with Crm1 is insensitive to estradiol. Thus, independently of estradiol, ER537F is retained in nuclei, where it entangles FKHR-driving cell cycle arrest. Chromatin immunoprecipitation analysis reveals that overexpression of ER537F in breast cancer cells enhances FKHR interaction with cyclin D1 promoter. This mutant also counteracts cell transformation by the activated forms of Src or PI3-K. In conclusion, in addition to regulating receptor localization, ERalpha phosphorylation by Src is required for hormone responsiveness of DNA synthesis in breast cancer cells.
INTRODUCTION
Subcellular localization of steroid receptors has been attracting increasing attention as investigation into the non-genomic action of steroid receptors revealed their ability to interact and activate signaling effectors. 1 In this context, the observation that steroid activation of signaling pathways regulates nuclear/cytoplasmic shuttling of glucocorticoid, progesterone and androgen receptors 2 as well as orphan estrogen receptor alpha-related protein 3 has a strong impact.
We reported that the nuclear export of estradiol receptor alpha (ERalpha) requires estradiol activation of the PI3-K/Akt pathway, consequent complex assembly of ERalpha with Forkhead in rhabdomyosarcoma (FKHR) and Crm1-dependent export of the complex in breast cancer cells. This process fosters DNA synthesis, as it removes the inhibitory action of FKHR on cell cycle. 4 IGF-1 activation of Akt-2 also controls nuclear localization of ERalpha and FKHR-like 1 (FKHR-L1) in MCF-7 cells. 5 We previously mapped within the 444 --456 sequence of ERalpha the nuclear export signal (NES) responsible for estradioldependent interaction of ERalpha with Crm1. 4 The hormonebinding domain of the receptor (ERalpha HBD) is endowed with ERalpha NES and also includes Tyr537. This residue is a crucial regulatory site for ERalpha activity as its phosphorylation has been implicated in ERalpha maximal hormone binding, dimerization and transcriptional activity. 6 --10 Tyr537 phosphorylation also controls estradiol-induced Src activation. 11 Src-related kinases regulate nuclear export of proteins involved in metabolic responses, stress-induced damage and aging, such as human telomerase reverse transcriptase, 12 Nrf2 and Bach1. 13 The present study defines the role of estradiol-dependent ER phosphorylation at Tyr537 in the nuclear export of ERalpha and proliferative activity through upregulation of cyclin D1 transcription.
RESULTS
Tyrosine 537 of ERalpha and Src activity regulate intracellular localization of the receptor in breast cancer cells As Tyr537 represents a regulatory site for ERalpha activity, we addressed its role in receptor localization. MCF-7 cells were transfected with the fusion protein GFP --ERalpha, wt or 537F, and the score of nuclear fluorescence was monitored before and after estradiol treatment. About 50% of GFP --ERalpha wt was localized in nuclei of untreated cells ( Figure 1a ) and endogenous ERalpha behaves like GFP --ER (see Lombardi et al. 4 ; Figure 3d ). These results are correlated to the quiescence conditions of cells, as the nuclear localization of endogenous ER (Supplementary Figure S1A) and GFP --ER ( Supplementary Fig. S1B ) increases with the increase in the basal level of BrdU incorporation in MCF-7 cells.
As reported, 4 30 min hormonal stimulation of MCF-7 cells increased the nuclear localization of GFP --ER to over 80%. The fraction of nuclear receptor was reduced back to about 50% upon 60 min hormonal stimulation. In contrast, GFP --ER537F was predominantly nuclear (80 --90%), regardless of hormonal stimulation. Images from this experiment are shown in Supplementary  Fig. S1C . A more prolonged estradiol stimulation (2 h and 4 h) did not modify intracellular localization of GFP --ER537F (not shown) and GFP alone was insensitive to estradiol treatment when overexpressed in MCF-7 cells (see Lombardi et al. 4 and Supplementary Fig. S1D ). Again, intracellular distribution of the two fusion proteins overexpressed in T47D ( Supplementary Fig. S1E ) and MDA-MB231 ( Supplementary Fig. S1F ) breast cancer cells are similar to those observed in MCF-7 cells, highlighting the conservation of the process through different human breast cancer-derived cells.
The 60 min estradiol-induced decrease of nuclear localization of GFP --ERalpha wt was not due to receptor proteolysis, as Figure 1b (upper) shows similar protein levels in whole lysates from MCF-7 cells expressing GFP --ERalpha, wt or 537F mutant, at the different times. Fractionation analysis confirmed that 60 min hormonal stimulation simultaneously decreases the amount of nuclear GFP --ER and increases its cytoplasmic levels (lower in Figure 1b , left). In contrast, the GFP --ER537F mutant was mostly detected in the nuclear fraction after 60 min hormone treatment (lower in Figure 1b , right).
Tyr537 mediates the estradiol-regulated interaction of ERalpha with Src in vitro and in vivo. It also controls Src-dependent pathway activation leading to DNA synthesis in breast cancer cells and tumor xenografts. 14, 15 We therefore hypothesized a role for Src activity in ERalpha nuclear export. MCF-7 cells were transfected with GFP --ERalpha, wt or 537F, along with a catalytically inactive Src. 16 This version of Src inhibits estradiol-induced DNA synthesis when transfected 14 ( Supplementary Fig. S8 ) or microinjected 17 in MCF-7 cells. Overexpression of Src K À , but not Src wt, traps GFP --ERalpha in nuclei of 60 min estradiol-treated MCF-7 cells (Figure 1c and Supplementary Fig. S2A ). Overexpression of a constitutively active form of Src (Src 537F) slightly increased the extra-nuclear localization of GFP --ER, whereas it did not affect the nuclear localization of GFP --ER537F mutant in MCF-7 cells ( Supplementary  Fig. S2B ).
Lastly, we used a 10 amino-acid p-Tyr peptide derived from the sequence surrounding the phosphotyrosine residue in position 537 of ERalpha. It specifically inhibits ERalpha/Src association and Src-dependent cell proliferation induced by estradiol in MCF-7 cells as well as the growth of MCF-7 cell xenografts. 15 The p-Tyr peptide induces nuclear retention of GFP --ERalpha in 60 min estradiol-treated MCF-7 cells (Figure 1d ), whereas the nonphosphorylated peptide did not affect trafficking of GFP --ERalpha. The p-Tyr peptide does not interact with NES contained in other proteins. Supplementary Fig. S3A shows that the peptide did not affect estradiol-induced nuclear export of NES-containing p27 18 in MCF-7 cells. Again, the peptide did not modify cytoplasmic localization of REV-NES ( Supplementary Fig. S3B ), in which the NES represents the canonical export sequence of the REV protein, derived from human immunodeficiency virus. 4, 18 These findings highlight the specific interference of P-tyr peptide in ERalpha nuclear export.
In sum, phosphorylation of ERalpha at Tyr537 and the catalytic activity of Src kinase are needed for estradiol-induced nuclear export of the receptor in breast cancer cells.
Src activity regulates the intracellular localization of ERalpha in NIH3T3 fibroblasts ERalpha-negative NIH3T3 cells (see Castoria et al. 17 ; Supplementary Fig.S4A ) were transfected with GFP --ERalpha, wt or 537F, and the score of nuclear fluorescence was monitored before and after 30 or 60 min of estradiol treatment. Intracellular distribution of both GFP --ER, wt or 537F, was similar to that observed in MCF-7 cells (compare Figures 1a and 2a) .
Again, in Src-transformed NIH3T3 cells (cSrcY527F; Roche et al. 19 ), we observed that irrespective of hormonal stimulation, GFP --ERalpha wt is predominantly localized in the extra-nuclear compartment of cells, whereas GFP --ER537F is retained in nuclei (Figure 2b) . Representative images are shown in Figure 2c and d.
Phosphorylation at tyrosine 537 controls the estradiol-induced nuclear export of ERalpha in Cos and MCF-7 cells Tyrosine phosphorylation status of ERalpha was analyzed by ectopic expression of ERalpha, wt or 537F, in Cos-7 cells. Immunoprecipitation experiment in Figure 3a shows strong tyrosine phosphorylation of ERalpha wt upon 30 min estradiol treatment, when ERalpha begins to exit from nuclei. 4 Albeit expressed at higher levels, ER537F was not recognized by the anti-p-Tyr antibodies (Figure 3a ) and was retained in nuclei of Cos cells (Figure 3b ). This experiment shows for the first time that in , d ), localization of GFP --ER, wt or ER537F mutant, was monitored by microscopy as described in Materials and methods. Cells that fell into the category of exclusively ER nuclear fluorescence were scored and data expressed as a percentage of transfected (a, d) or co-transfected (c) cells. In (a, c, d), data were derived from at least 1000 scored cells. Results of independent experiments were averaged; means and s.e.m. are shown. n represents the number of experiments. The statistical significance of results in (a, c, d) was also evaluated by Student's t-test. *P value o0.005; **P value o0.001. In (b), cells expressing GFP --ER, wt or 537F mutant, were treated with 10 nM estradiol for the indicated times. The upper section shows the western blot with the anti-GFP antibody of the corresponding whole lysates. Transfected cells were subjected to fractionation analysis. Nuclear (nucl) and cytoplasmic (cyt) fractions were then analyzed by western blot using the anti-GFP antibody (lower section in (b)). The corresponding levels of actin are shown.
addition to growth factors, 20, 21 estradiol induces tyrosine phosphorylation of ERalpha and this phosphorylation is restricted to Tyr537.
The NLS --HEG14 construct, lacking the amino-terminal half of ERalpha (ERalpha delta 1 --240; Supplementary Fig. S5A ), is exported from nuclei with the same kinetics as the full-length ERalpha ( Supplementary Fig. S5B ). This makes it unlikely that phosphorylation on tyrosine and serine residues present in this ERalpha sequence 22 --25 has a role in the estradiol-modulated nuclear export of ERalpha.
The effect of estradiol on tyrosine phosphorylation of endogenous ERalpha was analyzed by a time course experiment in MCF-7 cells. Supplementary Figure S5C shows that estradiol rapidly increases tyrosine phosphorylation of ERalpha. Phosphorylation persists up to 30 min and declines to basal levels upon 60 and 90 min hormonal treatment. Thereafter, MCF-7 cells were challenged for the indicated times with estradiol in the absence or presence of the selective Src kinase family inhibitor SU6656. 26 Figure 3c shows that estradiol rapidly induces (middle panel) or increases (lower panel) tyrosine phosphorylation of endogenous ERalpha. This phosphorylation persists up to 30 min of estradiol treatment. The difference in basal levels of ER tyrosine phosphorylation (compare middle and lower panels in Figure 3c ) might be caused by the ability of anti-P-Tyr antibodies to precipitate the tyrosine phosphorylated ER more efficiently than anti-ER antibodies. SU6656 prevents rapid (5 min) and persistent (30 min) ERalpha tyrosine phosphorylation. Consistently, SU6656 also prevents the 60 min estradiol-induced nuclear export of endogenous ERalpha (Figure 3d ) or GFP --ERalpha wt (not shown) in MCF-7 cells. These findings conclusively link Tyr537 phosphorylation by Src family kinases with the estradiol-regulated nuclear export of ERalpha.
Phosphorylation at tyrosine 537 controls the estradiol-induced interaction of ERalpha with both FKHR and Crm1
The best-characterized nuclear export pathway uses Crm1 as a receptor for proteins with leucine-rich NES and active Ran (Ran --GTP) positively affects interaction of NES containing proteins with Crm1. 27 To investigate the role of Tyr537 phosphorylation in the interaction of ERalpha with Crm1, we co-transfected MCF-7 cells with ERalpha, wt or 537F, along with Crm1. Cells were challenged for 30 min with estradiol. Lysate proteins were immunoprecipitated with anti-Crm1 antibody, then blotted with antibodies against the indicated proteins. Despite the presence of estradiol, we detected a negligible ER537F/Crm1 interaction, which was unaffected by active Ran (Ran --GTP), included as a GTPase-deficient RanQ69L mutant. 27 In contrast, Ran --GTP increased interaction of ERalpha wt with Crm1 ( Figure 4a ). Thus, receptor tyrosine phosphorylation modulates the interaction with Crm1 in the presence of estradiol. Similar findings were observed in Cos cells ( Supplementary Fig. S6A ).
We then speculated that Tyr537 phosphorylation of ERalpha mediates the binding of the receptor to Ran. MCF-7 cells were transfected with GFP --ERalpha wt or 537F mutant, then challenged for 30 min with estradiol. Immunoprecipitation experiment ( Figure 4b ) shows that estradiol stimulates association of ERalpha wt with Ran, whereas the ER537F mutant fails to do so. Similar results were obtained in Cos cells (Supplementary Fig. S6B ).
In estradiol-treated MCF-7 cells, ERalpha exits nuclei in complex with FKHR. 4 We therefore investigated whether Tyr537 phosphorylation mediates interaction of ERalpha with FKHR. Both ER mutants, ER14 (lacking the ER-amino terminal half) and ER15 (lacking the ER-carboxyl terminal half), associated with FKHR under basal conditions. Only the ER14 mutant, which is endowed with Tyr537, showed an estradiol-dependent increase in FKHR association ( Supplementary Fig. S6C ). Therefore, we transfected MCF-7 cells with GFP --ERalpha, wt or 537F mutant. Experiments in Figure 4c show that estradiol slightly increases interaction of ER537F with FKHR. In contrast, hormonal treatment significantly enhanced ERalpha wt/FKHR interaction. Similar findings were observed in transfected Cos cells (Supplementary Fig. S6D ).
FKHR requires ERalpha export to be efficiently exported in a Crm1-dependent fashion from nuclei of MCF-7 cells. 4 Thus, we speculated that ER537F, which is mostly localized in nuclear compartment of these cells and weakly interacts with Crm1, also induces nuclear retention of FKHR. Therefore, we transfected MCF-7 cells with Myc-tagged ERalpha, wt or 537F, together with GFP --FKHR wt. Fluorescence distribution of FKHR was monitored by confocal microscopy before and after 30 or 60 min of estradiol treatment. Figures 4d and e show that irrespective of estradiol treatment, GFP --FKHR was predominantly nuclear (about 80%) in cells expressing ER537F mutant. Images (f) show that upon 60 min estradiol stimulation, GFP --FKHR is retained in nuclei of ER537F-expressing MCF-7 cells. In contrast, estradiol induced a progressive nuclear release of GFP --FKHR in cells expressing ERalpha wt (Figure 4d ). GFP --FKHR did not affect the intracellular distribution of ERalpha, wt or 537F, in MCF-7 cells challenged with estradiol ( Figure 4e ). Thus, ER537F mutant slightly interacts with Crm1 because of its failure to interact with Ran. Further, ER537F mutant associates with FKHR in a hormone-independent fashion, thereby inhibiting its nuclear release in estradiol-treated cells.
The ER537F mutant abolishes estradiol-induced S-phase entry and counteracts the transforming ability of Src and PI3-K We then analyzed the ability of GFP --ER to mediate S-phase entry upon estradiol stimulation of MCF-7 cells. In cells expressing GFP --ERalpha wt, BrdU incorporation was stimulated from 12% to 59% by estradiol (Figure 5a ). No increase in BrdU incorporation was detected in estradiol-treated MCF-7 cells expressing GFP --ER537F. This failure to induce S-phase entry is not owing to GFP --ER537F proteolysis, as western blot (a) shows comparable amounts of GFP --ER537F in lysates from untreated or estradioltreated MCF-7 cells. GFP --ERalpha wt was revealed as comparison. NIH3T3 cells transfected with GFP --ERalpha, wt or ER537F, were analyzed to measure the increase in BrdU incorporation upon estradiol stimulation. As in Figure 5b , here again no hormonal stimulation was observed in cells transfected with GFP --ER537F (Figure 5b) .
We subsequently investigated the ability of ER537F to reduce fibroblast transformation induced by the constitutively active form of Src (Src527F 19 ), the membrane-targeted p110, p110CAAX, 28 or the activated form of MEK, MEK-EE. 29 Both the activated forms of Src and PI3-K consistently transform NIH3T3 fibroblasts (Figures 5c  and d) . Albeit less strongly than Src527 or p110CAAX, the activated MEK also induces transformation. In contrast with ERalpha wt (Figure 5c ), ER537F drastically reduced transformation by both p110 CAAX and Src 527 (Figures 5c and d) , suggesting that ER537F counteracts the transforming ability of Src or PI3-K probably by acting downstream of Src or PI3-K. As in Src-transformed NIH3T3 cells ER537F is persistently (by 60 min) localized in nuclei (Figures 2b and d) and has been detected in nuclei of NIH3T3 cells 7 days after transfection with Src527 and p110CAAX (not shown), it is conceivable that ER537F nuclear localization is responsible for the inhibitory action observed in focus assay. Transformation by the activated MEK is insensitive to ERalpha, wt or 537F mutant (Figure 5c ), suggesting that Src and PI3-K use alternative pathways to those used by MEK in transforming the cells. 16, 28 Kinetic differences in ER537F and FKHR binding to cyclin D1 gene promoter are associated with inhibition of estradiol-induced cyclin D1 transcription The ER537F mutant retains most of its ability to activate ERE-dependent transcription. In fact, ectopic expression of ERalpha, wt or 537F, enables ERalpha-negative NIH3T3 fibroblasts to activate an ERE-Luc reporter gene upon estradiol stimulation (Figure 6a ). The antiestrogen ICI inhibited this stimulation.
We then performed cyclin D1 ChIP/promoter construct experiments in breast cancer cells focusing on a locus involved in both FKHR 30 and estradiol 31 regulation. We first assessed the occupancy of this region by both endogenous ERalpha and FKHR in MCF-7 cells. Figure 6b shows that the occupancy of cyclin D1 gene promoter by endogenous ERalpha exhibits a sharp peak at 22 min of hormone stimulation, whereas FKHR binding to this site is significantly decreased. At 44 min, low levels of ERalpha and FKHR are observed. Use of the same locus in ER-negative MDA-MB231 cells ectopically expressing ERalpha wt (Figure 6c, upper) gave similar findings. In contrast, a persistent and hormone-insensitive binding of ERalpha 537F to cyclin D1 gene promoter is observed. FKHR recruitment to this gene promoter is enhanced to a much higher extent (Figure 6c, lower) . Notably, in Figure 6d we observed similar results by using a different locus (À253 to À50 bp) of CCDN1 gene. 32 We then evaluated the effect of ERalpha, wt or 537F mutant, on cyclin D1 promoter transcription. MCF-7 cells were transfected with the human cyclin D1 promoter along with GFP --FKHR, wt or FKHR --AAA, which permanently resides in cell nuclei, 4 or ERalpha, wt or 537F. Estradiol stimulates cyclin D1 transcription Figure 4 . The ER537F mutant weakly interacts with nuclear export machinery and traps FKHR in nuclei of MCF-7 cells. In (a --c), MCF-7 cells were transfected with plasmids encoding for GFP --ERalpha wt or 537F mutant. In (a), the cells were co-transfected along with HA --CRM1-encoding plasmid. The cells were made quiescent, then stimulated for 30 min with estradiol in the absence or presence of the purified recombinant RanQ69L (at 1 mM). Lysates were immunoprecipitated with anti-HA antibodies and eluted proteins were probed using anti-HA (CRM1) or anti-ER (ER) antibodies. The loading GFP --ER (wt or 537F) in the corresponding cell lysates was detected using anti-GFP antibody (input). In (b, c), the cells were made quiescent and then left unstimulated or stimulated for 30 min with estradiol. The upper panels in (b) show GFP --ER (wt or 537F) or Ran protein levels in the corresponding cell lysates (input). In the middle and lower panels, lysates containing similar amounts of Ran were immunoprecipitated with anti-Ran (anti-Ran) or mouse IgG (ctrl Ab) antibodies. Proteins in immunocomplexes were blotted using antibodies against Ran (middle panel) or ER (lower panel). In (c), lysates were immunoprecipitated using anti-ER antibody. Lysates were probed using antibodies against the indicated proteins. Data were analyzed using the NIH Image J program and expressed as relative increase. The estradiol-induced increase in the interaction between ER and FKHR was 2.27 fold for ER wt and 1.26 for ER537F mutant, respectively. In (d --f), MCF-7 cells on coverslips were used. The cells were co-transfected with the indicated plasmids, then made quiescent and left unstimulated or stimulated with 10 nM estradiol for the indicated times. Localization of GFP --FKHR wt, Myc --ER wt or Myc --ER537F mutant was monitored by confocal microscopy. Cells that fell into the category of exclusively FKHR (d) or ERalpha (e) nuclear fluorescence were scored and data expressed as a percentage of co-transfected cells. For each experiment in (d, e), data were derived from at least 500 scored cells. Results of independent experiments were averaged; means and s.e.m. are shown. n represents the number of experiments. The statistical significance of results in (d) and (e) was also evaluated by Student's t-test. *P value o0.001; **P value o0.005. In (f ), images from one experiment in (e) are shown. They represent the staining of Myc --ER537F (red) in MCF-7 cells co-expressing GFP --FKHR wt (green) and treated for 60 min with estradiol. Merged images are also shown in the right pictures. Bar, 5 mm. The effect of estradiol stimulation on intracellular distribution of FKHR, wt or AAA mutant, overexpressed in MCF-7 cells was analyzed by confocal microscopy. FKHR wt is released in cytoplasm upon 8 h of estradiol treatment ( Supplementary Fig.  S7A ), when cyclin D1 is almost completely upregulated by the hormone and cells enter S-phase. At that time point, the triple mutant FKHR --AAA is still retained in nuclei, thus reinforcing the role of FKHR nuclear retention in the loss of DNA synthesis and cyclin D1 transcription stimulated by estradiol.
We also considered that other targets of estradiol, such as p27 and c-Myc, implicated in FOXO 33 and ER 34 action might be involved. Expectedly, 35 estradiol does not modify p27 transcription ( Supplementary Fig. S7B ), but decreases p27 nuclear localization, which is unaffected by overexpression of the kinase-dead Akt (Akt K À ) or FKHR --AAA ( Supplementary Fig. S7C ) in MCF-7 cells. Here again, ERalpha, wt or 537F, similarly mediates estradiol-induced Myc expression (Supplementary Fig. S7D ). Finally, silencing of cyclin D1 in MCF-7 cells drastically inhibits (90%) estradiol-elicited S-phase entry, while it reduces (50%) serum-induced DNA synthesis in MCF-7 cells (Supplementary Fig. S9) .
Thus, the ER537F mutant persistently binds the cyclin D1 promoter in ChIP assay and FKHR is simultaneously recruited to this gene promoter. Both these events are associated with cyclin D1 downregulation and cell cycle arrest.
DISCUSSION
We here report that estradiol-stimulated Src activity is responsible for in vivo ERalpha Tyr537 phosphorylation, thus driving nuclear export of the receptor. The Src inhibitor, SU6656, and a dominant- After in vivo pulse with BrdU, DNA synthesis was analyzed by immunofluorescence and calculated as in the legend to panel (a). In (a, b) data were derived from at least 1000 scored cells. Results of several independent experiments were averaged; means and s.e.m. are shown. n represents the number of experiments. The statistical significance of results in (a, b) was also evaluated by Student's t-test. *P value o0.001. The upper panel in (b) shows the western blot with anti-GFP antibody of cell lysates. Lysate from cells transfected with GFP alone was analyzed as a control (ctrl). In (c), NIH3T3 cells were transfected with p110 CAAX (p110*) or Src 527F (Src 527) or MEK-EE in the absence or presence of either pSG5 or pSG5-HEG0 (ER wt) or pSG5-ER 537F (ER 537F). Control cells (ctrl) were transfected with the empty pSG5 plasmid alone. After 12 days, the cells were stained with 0.5% crystal violet. Quantitation plotted in (c) is the means with standard errors of duplicate assays and is representative of three independent experiments. Representative plates are shown in (d).
negative Src both inhibit estradiol-induced tyrosine phosphorylation and ERalpha nuclear export in estradiol-treated cells. A p-Tyr peptide mimicking the sequence of ERalpha surrounding tyrosine 537 15 prevents estradiol-induced ERalpha nuclear export. Thus, the hormonal control of ER nuclear exclusion occurs through Src-dependent Tyr537 phosphorylation of the receptor. The behavior of ERalpha 537F mutant fits with these conclusions. In contrast with the wild-type, this mutant, which is not phosphorylatable on tyrosine, persistently (by 60 min) localizes in nuclei when ectopically expressed in different cell types. In turn, the nuclear localization of the wild-type receptor is reduced in MCF-7 cells overexpressing a constitutively active form of Src or in Src-transformed NIH3T3 cells. This result is of interest as Src activation occurs in human mammary cancers 36 and extra-nuclear ERalpha has a proliferative role. 37 The nuclear localization of ER537F is insensitive to Src activity. Our findings reveal that Tyr537 phosphorylation by Src enhances the hormone-dependent interaction of ERalpha with Ran --GTP, thus enabling the interaction of NES-ERalpha with Crm1. These data unravel the as yet unknown role of tyrosine phosphorylation in controlling ERalpha nuclear export.
Evidence in breast cancer MCF-7 cells supports a dominantnegative effect of the ER537F mutant on endogenous ERalpha. This is reminiscent of ERalpha delta 3 isoform. 38 The delayed halflife of the mutant as compared with that of the wt receptor and/or the assembly of inactive heterodimers made up of the wild-type and the mutant ERalpha could explain this behavior. Endogenous ER undergoes degradation upon 4 h hormonal stimulation and SU6656 prevents this degradation in MCF-7 cells ( Supplementary  Fig. S8A ). In the same cells, the ER537F mutant is expressed at higher levels as compared with the wild-type (Figures 3, 5, 7 and Supplementary Fig S4) . Again, in MCF-7 cells overexpressing ER537F, neither the mutant nor endogenous ER undergo degradation, as occurs upon 4 h hormonal treatment of cells transfected with ER wt. SU6656 prevents Src-dependent ER wt degradation, leaving unaffected the levels of ER537F, thereby promoting the assembly of heterodimers. In agreement with previous findings, 39 our results indicate that ERalpha is targeted by Src for degradation. Furthermore, they identify Tyr537 as the target of Src, which triggers estrogen-dependent ERalpha proteolysis in human breast cancer cells.
Expectedly, 40 the ER537F mutant retains most of its ability to activate ERE-dependent transcription. Previous papers reported that different substitutions in this residue differently affect ER transcriptional activity. Two of the ER mutants, Y537A and Y537S, showed 20--100% transcriptional activity in the absence of estrogen. Thus, some amino-acid substitutions at Tyr537 can also induce changes in ER functions, mimicking the receptor properties normally regulated by estradiol. 41, 42 The finding that ER537F mutant mediates ERE-Luc activation and c-Myc expression, but fails to mediate cyclin D1 upregulation in response to estradiol suggests that FKHR recruitment by ER537F represses cyclin D1 transcription. The failure of ER537F mutant to be exported from nuclei in complex with FKHR could fully channel FKHR towards cyclin D1 promoter, thereby facilitating the FKHR repressor function. ChIP/promoter construct experiments support these conclusions. The role of Tyr537F phosphorylation in driving cell cycle progression is reinforced by the finding that ER537F mutant does not mediate either cyclin D1 transcription or S-phase entry in estradiol-challenged MCF-7 cells. Supplementary data ( Supplementary Fig. S8 ) further support this conclusion, showing that a dominant-negative Src and a Src inhibitor, SU6656, prevent cyclin D1 upregulation and DNA synthesis induced by estradiol in MCF-7 cells. Given that Tyr537 is the only estradiol-dependent phosphorylated residue (Figure 3a) , our results corroborate each other in showing that Tyr537 phosphorylation impacts cell cycle progression of breast cancer cells.
Although Akt-activated FKHR increases p27 transcription, 33 estradiol activation of the Akt/FKHR pathway does not controlp27 transcription or modify its subcellular localization. In addition, ER wt or 537F both mediate estradiol-induced c-Myc expression.
Therefore, cyclin D1 upregulation by the ERalpha/FKHR complex is the master event in driving G1 --S progression of breast cancer cells. Cyclin D1 siRNA experiments ( Supplementary Fig. S9 ) strengthen this view. ERalpha can be de-phosphorylated in the nucleus by a phosphotyrosine phosphatase. 43 The role of phosphotyrosine phosphatases in regulating the level of phosphorylated ERalpha and associated proliferative activity has been established in MCF-7 cells treated with the phosphotyrosine phosphatase inhibitor, orthovanadate. 44 We speculate that an ERalpha fraction undergoes de-phosphorylation. 44 Once de-phosphorylated, the receptor, like 537F mutant, could downregulate DNA transcription via FKHR. In this way ER de-phosphorylation might contribute to the sequential and combinatorial assembly of transcriptionally productive complexes on a promoter. 45 Under physiological conditions, this process might represent a protective mechanism against exceeding or untimely expression of proteins (that is, cyclin D1) required for DNA synthesis induced not only by the hormone, but also by growth factors. Non-phosphorylatable ER could also exert a dominant-negative action in reducing response to powerful transforming signals, possibly through its nuclear residency. Thus, non-phosphorylated ERalpha might act as a tumor suppressor, like the oncoprotein pRb, whose dephosphorylated form turns on tumor suppressor activity. 46 Lastly, accumulation of non-phosphorylated ERalpha could be involved in the loss of hormone responsiveness. In aggressive human mammary cancers, we detected large amounts of non-phosphorylated ERalpha. 47 In addition, much higher non-phosphorylated ERalpha levels were found in hormone-independent tumors than in hormone-dependent and -responsive carcinomas from GR mice. 48 A large increase in non-phosphorylated receptor levels also correlates with relapse of human mammary cancer. 47 The present and previous reports show that two estradiolactivated kinases contribute to nuclear export of the ERalpha/ FKHR complex. AKT phosphorylates FKHR 4 and Src phosphorylates ERalpha. These phosphorylations regulate the estradiol-stimulated ERalpha/FKHR complex assembly and its interaction with Crm1. These events finally lead to downregulation of FKHR transcriptional activity and initiation of DNA synthesis.
MATERIALS AND METHODS Constructs
The wild-type pSG5-h ERalpha, HEG0, 49 the ERalpha mutants, HEG14 and HEG15 49 and the construct NLS/HEG14 were in pEGFP 4 or pSG5-Myc. 35 Point-mutated ERalpha in pSG5 (Tyr 537F 7 ) was in pEGFP 6 or pSG5Myc. 35 The wt (Src wt), the kinase-inactive (Src K À ) and the kinase-active (Src 527F) forms of Src were in pSG5. 16, 19 The Myc --His-tagged dominant-negative Akt (K179M) in the pUSEAmp was from UBI (Upstate Biotechnology Inc., Lake Placid, NY, USA). The wild-type HA-tagged Akt was in pSG5. 35 FKHR, wild-type or the mutant FKHR --AAA, in pCDNA-GFP was from Add gene (Cambridge, MA, USA). Constitutively active RanQ69L was in pQE plasmid 50 and pCDNA/HA-Crm1 51 was in pSG5. 4 REV-NES was in pEGFP. 18 Cell culture, transactivation assays and siRNA
Low passage MCF-7, T47D, MDA-MB231, NIH3T3 and Cos-7 cells were cultured and made quiescent. 14, 17 Only the cells that under basal conditions incorporated less than 15% BrdU were used. Growing NIH3T3, Src-transformed 19 and Cos-7 cells were transfected as described. 14, 17 Quiescent MCF-7 or T47D or MDA-MB231 cells were transfected with 1 mg of each purified plasmid using the Superfect reagent. Src, wt or K À or 527F, and GFP --FKHR, wt or FKHR --AAA mutant, were co-transfected at 0.5 mg. After transfection, the cells were incubated at 37 1C for 24 h and used. For transactivation assay in NIH3T3 cells, 2 mg of pGL2 ERE-Luc were co-transfected. Cells were made quiescent and used. Transactivation assay in MCF-7 cells was performed using the full-length human cyclin D1 (pGL2-cyclin D1-Luc, provided by R Assoian) or p27 (pGL2-p27-Luc, Figure 7 . The ER 537F and FKHR --AAA mutants weakly mediate estradiol action on cyclin D1 upregulation and DNA synthesis in MCF-7 cells. MCF-7 cells were used. In (a --c), the cells were transfected with the indicated plasmids in the presence (a, b) or absence (c) of the full-length human cyclin D1 promoter (cyclin D1-Luc). Cells were made quiescent and then left untreated or treated with 10 nM estradiol. After 3 h, lysates were analyzed for luciferase activity (a) or cyclin D1 expression (b). Upper panels in b show the levels of cyclin D1 in FKHR (wt or AAA mutant; left section) or ER (wt or 537F mutant; right section) transfected cells. Lower panels in (b) show cyclin D1 levels in cells transfected with the control vectors (pCDNA or pSG5). The corresponding levels of tubulin (tub) are shown. In (c), after 18 h, transfected cells on coverslips were analyzed for BrdU incorporation, which was calculated as described in the legend to Figure 5 . In (a, c), data from several independent experiments were analyzed. Means and s.e.m. are shown; n represents the number of experiments.
